Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,113,061
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 8,233,044	$ 11,433,579
Restricted cash	100,000	0
Accounts receivable (net of allowance of $95,477 and $94,838 as of March 31, 2015 and December 31, 2014, respectively)	5,845	220,534
Inventory (net of reserves of $1,408,453 as of March 31, 2015 and December 31, 2014)	5,187,926	5,274,803
Prepaid expenses and other current assets	350,165	274,031
Total Current Assets	13,876,980	17,202,947
Property and equipment, net	1,620,365	1,961,376
Patents and trademarks, net	35,450	36,719
Deferred financing costs	640,981	820,775
Other assets	48,000	48,000
Total Assets	16,221,776	20,069,817
Current Liabilities:
Accounts payable (includes related parties of $67,500 and $73,792 as of March 31, 2015 and December 31, 2014, respectively)	1,320,274	1,239,919
Accrued expenses	651,186	841,918
Deferred revenue	25,391	42,843
Warrant liability	1,833,638	499,089
Other current liabilities	54,434	61,829
Total Current Liabilities	3,884,923	2,685,598
Long Term Liabilities:
Deferred revenue	16,420	26,500
Deferred rent	70,075	80,084
Senior secured convertible debentures (net of discount of $6,395,105 and $8,410,187 at March 31, 2015 and December 31, 2014, respectively)	4,707,410	5,000,826
Total Long Term Liabilities	4,793,905	5,107,410
Total Liabilities	8,678,828	7,793,008
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity:
Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 10,279 at March 31, 2015 and 11,787 at December 31, 2014	1,028	1,179
Common stock - $0.001 par value; authorized 50,000,000 shares: Issued and outstanding 7,525,146 shares at March 31, 2015 and 6,037,232 at December 31, 2014	7,525	6,037
Additional paid-in capital	197,100,186	194,562,963
Accumulated deficit	(189,565,791)	(182,293,370)
Total Stockholders' Equity	7,542,948	12,276,809
Total Liabilities and Stockholders' Equity	$ 16,221,776	$ 20,069,817

BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for accounts receivable, current	$ 95,477	$ 94,838
Inventory, net of reserves	1,408,453	1,408,453
Accounts payable, related parties	67,500	73,792
Senior secured convertible debentures, discount	$ 6,395,105	$ 8,410,187
Preferred Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	10,279	11,787
Preferred Stock, Shares Outstanding	10,279	11,787
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	7,525,146	6,037,232
Common Stock, Shares, Outstanding	7,525,146	6,037,232

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
STATEMENTS OF OPERATIONS (USD $)	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net revenues	$ 81,200	$ 97,638
Cost of revenue	710,880	918,523
Gross profit	(629,680)	(820,885)
Operating expenses:
Research and development	238,874	707,824
Selling, general and administrative	2,762,991	3,203,533
Total operating expenses	3,001,865	3,911,357
Operating loss	(3,631,545)	(4,732,242)
Other income (expenses):
Interest income	1,126	618
Interest expense	(2,324,963)	(1,199)
Change in fair value of warrant liability	(1,334,549)	137,142
Registration rights liquidating damages	0	(3,389,940)
Other income, net	17,510	5,025
Nonoperating Income (Expense)	(3,640,876)	(3,248,354)
Net loss	$ (7,272,421)	$ (7,980,596)
Basic and diluted net loss per common share	$ (1.12)	$ (1.63)
Basic and diluted weighted average number of common shares outstanding	6,471,906	4,892,641

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
STATEMENTS OF CASH FLOWS (USD $)	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (7,272,421)	$ (7,980,596)
Adjustments to reconcile net loss:
Depreciation and amortization	316,243	696,800
Bad debt expense	639	700
Share-based compensation	230,062	164,168
Amortization of debt discount	2,015,082	0
Amortization of deferred financing costs	179,794	0
Change in fair value of warrant liability	1,334,549	(137,142)
Changes in operating assets and liabilities:
Restricted cash	(100,000)	0
Accounts receivable	214,050	22,330
Inventory	112,914	(16,815)
Prepaid expenses and other current assets	(76,134)	414,558
Accounts payable and accrued expenses	(110,377)	(192,101)
Other current liabilities	(7,395)	(6,119)
Deferred rent	(10,009)	(10,009)
Deferred revenue	(27,532)	(76,661)
Net cash used in operating activities	(3,200,535)	(7,120,887)
Cash flows from investing activities:
Purchases of property and equipment	0	0
Net cash used in investing activities	0	0
Cash flows from financing activities:
Net proceeds from private placements/public offerings	0	11,460,715
Net cash provided by financing activities	0	11,460,715
Net (decrease)/increase in cash and cash equivalents	(3,200,535)	4,339,828
Cash and cash equivalents at beginning of period	11,433,579	3,782,881
Cash and cash equivalents at end of period	8,233,044	8,122,709
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	139,000	0
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Conversion of convertible preferred stock into common stock	1,508,000	0
Conversion of senior secured convertible debentures into common stock	2,308,498	0
Reclassification of MelaFind components from property and equipment to inventory, net	$ 26,037	$ 0

ORGANIZATION AND BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

ORGANIZATION AND BASIS OF PRESENTATION

1. ORGANIZATION AND BASIS OF PRESENTATION

The Company is a medical technology company dedicated to designing and developing innovative software-driven technology for the early detection and prevention of skin cancer. The Company is focused on the commercialization of its flagship product, the MelaFind^® System, or (“MelaFind”), as well as the further design and development of this technology. MelaFind is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been “trained” by the Company’s proprietary database of melanomas and benign lesions. This result provides information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

Sales of MelaFind have not met the Company’s expectations. Beginning in 2013, the Company undertook several steps that it believes may significantly improve MelaFind’s commercial acceptance by: 1) changing its business model from solely a rental-based model to include a capital sales option; 2) refocusing its marketing efforts on medical dermatology, and particularly those dermatologists who treat patients at high risk for melanoma; and 3) beginning the process of obtaining a coverage determination from the Centers for Medicare & Medicaid Services (“CMS”), the federal agency that administers Medicare, in order to obtain reimbursement by Medicare and ultimately by private insurers for the use of MelaFind. During 2014, the Company made significant strides in each of these areas, although it anticipates that it will require a few years of continued effort before the success of this strategy can be assessed. Specifically, the Company anticipates that the insurance reimbursement process could take several years to complete.

In July 2014, MELA announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing MelaFind as an aid in the detection of melanoma. The Company submitted an application for a Current Procedural Terminology (“CPT”) code, which is necessary for Medicare Part B reimbursement by the Centers for Medicare and Medicaid Services (“CMS”). On March 9, 2015, the February 2015 CPT^® Editorial Summary of Panel Actions was posted to the website of the American Medical Association (the “AMA”). The CPT Editorial Panel accepted the addition of Category III codes 039XX1T and 039XX2T to report MSDSLA of atypical cutaneous lesions, which applies to MelaFind. Barring any further action by the Panel, the Company expects that these codes will be posted to the AMA CPT website by July 1, 2015, with an effective date of January 1, 2016, and will provide the basis for pursuing third party and CMS insurance coverage for MelaFind. Efforts to obtain reimbursement from private insurers are underway, but could take several years to complete.

During the first quarter of 2015, the Company voluntarily removed certain aspects of MelaFind’s user interface on systems in service in the United States after completing an internal review of the device’s Pre-Market Approval (“PMA”) requirements related to the user interface. The Company took this voluntary action in order to facilitate FDA review of other aspects of MelaFind’s user interface. Upon the completion of the review, the Company will re-assess and make appropriate revisions to the user interface. Our MelaFind systems in use outside the United States were not affected by this action.

On March 26, 2015, the Company implemented a plan of termination that resulted in a workforce reduction of nine employees in order to reduce operating costs. The workforce reduction was completed by April 1, 2015, which was the termination date for all of the affected employees. As a result of the workforce reduction, the Company accrued severance-related charges of $110,000 in the first quarter of 2015. Substantially all of the severance-related charges are expected to be paid during the second quarter of 2015.

Until the Company obtains insurance reimbursement from the CMS and private insurers, it expects that revenues will not be sufficient to cover operating and other expenses. The Company’s financial success will depend on a number of factors, primary among which is the ability to sell MelaFind, increase the penetration with dermatologists, encourage the usage of these systems, and control costs. Currently, the Company cannot determine when it will have sufficient revenues to cover continuing developmental costs, manufacturing, marketing and other operational expenses and has experienced recurring losses and negative cash flow from operations. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to operate and to meet its obligations in the ordinary course of business. In February 2014, the Company raised net proceeds of approximately $11.5 million from the sale of Series A convertible preferred stock and warrants to purchase common stock to strengthen the Company’s financial position (see Footnote 11 “STOCKHOLDERS’ EQUITY”). In July 2014, the Company issued Series B convertible preferred stock, senior secured convertible debt and warrants, raising an additional $13.8 million in net proceeds (see Footnote 9 “DEBT”). The proceeds from the sale of the Series B convertible preferred stock were used to redeem all outstanding shares of Series A convertible preferred stock.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. Interim results may not be indicative of the results that may be expected for the year. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its cash resources to the development and marketing of the MelaFind system and general and administrative expenses, and to date it has not generated any significant revenues from the sale of products. As a result, MELA has an accumulated deficit of $189,565,791 as of March 31, 2015. The Company’s recurring losses from operations and the accumulated deficit raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Even if the Company succeeds in commercializing the MelaFind system it may never become profitable. The Company expects to continue to incur significant losses over the next several years.

ORGANIZATION AND BASIS OF PRESENTATION (Detail Narrative) (USD $)	1 Months Ended		3 Months Ended
	Jul. 31, 2014	Feb. 28, 2014	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Accrued severance-related charges			$ 110,000
Proceeds From Sale Of Convertible Preferred Stock Common Stock And Warrants	13,800,000	11,500,000
Accumulated deficit			$ 189,565,791	$ 182,293,370

INVENTORY (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory, Gross	$ 6,596,379	$ 6,683,256
Inventory, Net	5,187,926	5,274,803
Mela Find Systems [Member]
Inventory [Line Items]
Inventory, Gross	3,197,421	3,266,586
Reserve for inventory	(325,000)
Components/raw materials [Member]
Inventory [Line Items]
Inventory, Gross	2,552,612	2,552,612
Accessories [Member]
Inventory [Line Items]
Inventory, Gross	496,346	514,058
Hand Held Imager Assemblies [Member]
Inventory [Line Items]
Inventory, Gross	350,000	350,000
Obsolete Inventory [Member]
Inventory [Line Items]
Reserve for inventory	(869,894)	(869,894)
Inventory Repairs [Member]
Inventory [Line Items]
Reserve for inventory	$ (538,559)	$ (538,559)

INVENTORY (Details Narrative) (USD $)	Mar. 31, 2015
Mela Find Systems [Member]
Inventory [Line Items]
Inventory Reserves	$ 325,000
Phantom Fixture Finished Goods [Member]
Inventory [Line Items]
Inventory Reserves	280,344
Phantom Fixture Assemblies Work In Progress [Member]
Inventory [Line Items]
Inventory Reserves	$ 264,550

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	3 Months Ended
PROPERTY AND EQUIPMENT, NET (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Gross	$ 6,913,471	$ 7,152,439
Accumulated depreciation and amortization	(5,293,106)	(5,191,063)
Net	1,620,365	1,961,376
Leasehold Improvements [Member]
Gross	905,888	905,888
Estimated Useful Life	Lease Term
Laboratory and Research Equipment [Member]
Gross	1,083,661	1,083,661
Estimated Useful Life	3-5 years
Office Furniture and Equipment [Member]
Gross	1,969,454	1,969,454
Estimated Useful Life	3-5 years
Mela Find Systems [Member]
Gross	$ 2,954,468	$ 3,193,436
Estimated Useful Life	5 years

PROPERTY AND EQUIPMENT, NET (Details Narrative) (USD $)	3 Months Ended
PROPERTY AND EQUIPMENT, NET (Details Narrative) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013 Components/raw materials [Member] Mela Find Systems [Member]
Property, Plant and Equipment [Line Items]
Inventory, Gross	$ 6,596,379		$ 6,683,256	$ 5,401,866
Net movements of MelaFind systems from property and equipment to inventory	26,037	0
Depreciation	$ 314,974	$ 695,531

NET LOSS PER COMMON SHARE (Detail)	3 Months Ended
NET LOSS PER COMMON SHARE (Detail)	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	22,708,493	3,866,367
Common Stock Purchase Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	13,078,920	2,104,767
Common Stock Equivalents of Convertible Debebtures [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	4,328,466
Common Stock Equivalents of Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	4,007,406	1,464,287
Common Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	1,293,701	290,801
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents		6,512

STOCK-BASED COMPENSATION (Detail)	3 Months Ended
STOCK-BASED COMPENSATION (Detail)	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Expected life		6 years 6 months
Expected volatility	0.00%	75.51%
Risk-free interest rate - Minimum		2.14%
Risk-free interest rate
Risk-free interest rate - Maximum		2.45%
Dividend yield

STOCK-BASED COMPENSATION (Detail Narrative)) (USD $)	3 Months Ended
STOCK-BASED COMPENSATION (Detail Narrative)) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 230,062	$ 164,168
Stock-based compensation net of forfeitures	26,951	35,296
Non-employee stock-based compensation		19,452
Unrecognized compensation expense	$ 1,027,470
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry period of option plans	10 years

DEBT (Details Narrative) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
DEBT (Details Narrative) (USD $)	Jul. 21, 2014	Mar. 31, 2015	Dec. 31, 2014
Senior Secured Convertible Debentures, amount	$ 15,000,005
Common stock, stated value per share		$ 0.001	$ 0.001
Debentures converted to common stock	5,847,955	899,999
Debenture converted to common stock, conversion price	$ 2.565
Fair value of warrant obligation	5,296,345
Security agreement date	Jul. 21, 2014
Intrinsic value of beneficial conversion feature on Debentures	4,565,350
Fair Value of Warrants issued to the placement agent for services rendered	491,228
Initial carrying value of Debentures	4,647,082
Initial debt discount on debentures	10,352,923	6,395,105	8,410,187
Amortization period of Debentures		5 years
Exercise prices		$ 2.57	$ 1.20
Risk free interest rate of return		1.37%	1.65%
Debentures converted to common stock, value		2,308,498
Increased interest expense		1,731,618
Outstanding amount of Debentures		$ 11,102,515
Debenture [Member]
Accrued interest rate		4.00%
Warrant Obligation [Member]
Stock prices		$ 2.44
Volatility		93.46%
Maturity period		5 years
Exercise prices		$ 2.45
Risk free interest rate of return		1.62%
Series A- Warrants [Member]
Warrants issued to purchase common stock	6,198,832
Common stock, stated value per share	$ 0.001
Warrants issued to purchase common stock, exercise price	$ 2.45
Warrant expiration period	2019-07

REVERSE SPLIT OF COMMON STOCK (Details Narrative)	0 Months Ended	3 Months Ended
REVERSE SPLIT OF COMMON STOCK (Details Narrative)	Jul. 09, 2014	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Reverse stock split, common stock		On July 9, 2014, the Company effected a previously authorized 1-for-10 reverse stock split of its common stock.
Reverse stock split ratio, common stock	0.1
Reverse stock split, effective date	Jul. 10, 2014

STOCKHOLDERS' EQUITY (Details) (USD $)	3 Months Ended
STOCKHOLDERS' EQUITY (Details) (USD $)	Mar. 31, 2015
Total Warrants	13,078,920
Common Stock Warrant One [Member]
Issue Date	Apr. 26, 2013
Expiration Date	Apr. 26, 2018
Total Warrants	69,321
Ex. Price	$ 11.18
Common Stock Warrant Two [Member]
Issue Date	Oct. 31, 2013
Expiration Date	Apr. 30, 2019
Total Warrants	685,715
Ex. Price	$ 8.50
Common Stock Warrant Three [Member]
Issue Date	Feb. 05, 2014
Expiration Date	Feb. 05, 2019
Total Warrants	1,329,731
Ex. Price	$ 7.40
Common Stock Warrant Four [Member]
Issue Date	Jul. 24, 2014
Expiration Date	Jul. 24, 2019
Total Warrants	6,198,832
Ex. Price	$ 2.45
Common Stock Warrant Five [Member]
Issue Date	Jul. 24, 2014
Expiration Date	Jan. 24, 2016
Total Warrants	4,795,321
Ex. Price	$ 2.45

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	3 Months Ended					1 Months Ended	3 Months Ended						0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jul. 24, 2014	Mar. 31, 2015 Series B warrants [Member]	Oct. 29, 2013 Series A Warrants [Member]	Mar. 31, 2015 Series A Warrants [Member]	Mar. 31, 2014 Series A Warrants [Member]	Mar. 31, 2015 Series B Preferred Stock [Member]	Dec. 31, 2014 Series B Preferred Stock [Member]	Jul. 24, 2014 Series B Preferred Stock [Member]	Jul. 24, 2014 Series A Preferred Stock [Member]	Feb. 05, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, par value	$ 0.10		$ 0.10										$ 0.10
Preferred stock, shares issued	10,279		11,787						10,279	11,787			12,300
Preferred stock, shares outstanding	10,279		11,787						10,279	11,787
Preferred stock converted in common stock									1,508
Conversion of convertible preferred stock											12,300	12,300
Conversion of convertible preferred stock, per share											$ 1,000		$ 1,000
Conversion of convertible preferred stock, initial price											$ 2.565		$ 8.40
Common stock issued on conversion of preferred stock				4,795,321					587,915				1,464,287
Warrants issued to purchase common stock											4,795,321		1,329,731
Warrants issued to purchase common stock, exercise price						$ 8.50					$ 2.45		$ 7.40
Proceeds from issuance of warrants													$ 11,457,831
Warrants issued, exercisable term													5 years
Fair value of warrants	1,223,352						610,286
Change in fair value of warrants, benefit	957,406						377,143	137,142
Liquidated damages paid	0	3,389,940
Preferred stock value allocated	1,028		1,179		12,300,000
Total preferred stock value									2,486,780
Preferred stock allocated to intrinsic value of beneficial conversion									1,887,364
Common stock, shares authorized	50,000,000		50,000,000
Common stock, par value	$ 0.001		$ 0.001
Common stock issued	7,525,146		6,037,232			422,819
Common stock outstanding	7,525,146		6,037,232
Proceeds from purchase agreement						$ 6,000,000
Aggregate Consideration Receivable For Warrants To Be Issued						685,715

FAIR VALUE OF FINANCIAL INSTRUMENTS (Detail) (USD $)	3 Months Ended	12 Months Ended
FAIR VALUE OF FINANCIAL INSTRUMENTS (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock Price	$ 2.57	$ 1.20
Risk-free Rate	1.37%	1.65%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility (Annual)	81.02%	72.90%
Time to Maturity (Years)	3 years 10 months 6 days	4 years 1 month 6 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility (Annual)	81.34%	88.10%
Time to Maturity (Years)	4 years 29 days	4 years 3 months 29 days

SUBSEQUENT EVENTS (Detail narrative) (Convertible Preferred Stock [Member], Subsequent Event [Member])	1 Months Ended
	Apr. 30, 2015
Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock	1,508
Conversion to common stock, shares	587,915